ASX upgrades surge on strong results, FDA wins fuel select stocks

September’s upgrade wave looks less like a blind reach for risk than a broker response to companies delivering numbers that forced models higher, with broker confidence in September’s upgrade wave tied to stronger-than-expected FY26 performance and guidance, supporting re-rating for upside. The Motley Fool Australia reported Morgans “put a buy rating and $25.00 price target on Megaport's shares” after being “impressed with its performance in FY 2026 and its guidance for the year ahead,” with MP1’s “FY26 underlying EBITDA and FY27 EBITDA guidance above market expectations,” while Monadelphous kept its “buy rating and $35.80 price target” after “FY26 was strong with EBITDA +49% YoY and NPAT +60%."

What turns better results into re-ratings is improved visibility: Morgans said that while “at first glance, simple maths suggests MP1's funding position looks tight,” “there is nearly $500m of additional funding that got lost in translation,” supporting expectations of surplus liquidity, and it argued Monadelphous’ “E&C order book has more than doubled YoY to nearly $1.2bn” so “strong growth will continue into FY27 and beyond.” That confidence is showing up despite volatility, with brokers indicating “continued confidence in several ASX 200 shares this week” even as the S&P/ASX 200 Index was “down 1.5% to 8,780.4 points on Thursday.”

The upgrades were grounded first in earnings delivery that made near-term forecasts look more credible. The Motley Fool Australia reported Bell Potter was “pleased to see that Mesoblast's Ryoncil product is building momentum,” after 4Q26 revenue reached US$36 million, up 20% on 3Q26 and in line with forecast, while FY26 Ryoncil revenue totalled US$115 million, the midpoint of guidance of US$110 million to US$120 million; Bell Potter’s renewed bullish stance and shift of Mesoblast to a Buy from Speculative Buy was tied to stronger FY26 earnings visibility from Ryoncil revenue momentum and results tracking guidance, with the broker saying strong revenue growth meant the speculative risk label was “no longer warranted.”

Just as important, brokers were rewarding stronger liquidity and funding visibility that shortened the path to growth. Bell Potter’s Mesoblast case extended beyond FY26 sales into a better financial trajectory, with FY27 Ryoncil sales forecast at US$275 million versus an annualised exit rate of US$144 million, which Bell Potter expected to be achievable due to the “expansion of the key account manager team… 6 additional FTEs being hired to service large markets in the north eastern US and California,” supported by traction with larger US transplant centres, while Judo Capital’s appeal rested on guided FY26 PBT of $163 million to $169 million and FY27 PBT of $210 million to $220 million; in September, NextDC added the clearest capital signal, pairing record FY26 numbers with a $1.1 billion funding boost.

The sharpest upside cases were often driven not by broad market optimism but by discrete regulatory and product de-risking events that clarified the path to commercialization. The Motley Fool Australia said 4DMedical’s outlook was “very positive” because “CT:VQ obtained US Food and Drug Administration (FDA) clearance in 2025,” after which it “has secured deployments with six leading US academic medical centres,” while Bell Potter highlighted that “Product revenues of $6.9m includes $1.6m in fee for service revenues… billed for CT:VQ on a fee per scan basis,” adding that this “initial traction… as highly meaningful” and expected to “grow.” Bell Potter’s Mesoblast thesis was even more explicit: “The key overhang on the stock remains clinical trial risk with three massive valuation events over the next 18 months being” pivotal milestones that could progressively remove uncertainty.

That same pattern appeared in smaller healthcare names, where approvals and access decisions were treated as foundations for adoption rather than mere background news. Lumos said FebriDx won U.S. FDA CLIA waiver status and nationwide Medicare reimbursement recognition across all Medicare Administrative Contractors (MACs), milestones that “materially expanded the addressable market opportunity for FebriDx by more than 15 times to over US$1.0 billion per annum,” and Bell Potter “has a price target of 25 cents on Lumos, compared to the current price of 10 cents”; likewise, Bell Potter’s most aggressive healthcare upside call on Clarity Pharmaceuticals was tied to a clear regulatory pathway, with Phase 3 data expected to support a New Drug Application for 64Cu SAR bis PSMA and approval framed as the key de-risking step.

The upside narrative on ASX shares is undeniably large, but it is also highly selective. The Motley Fool Australia captured that range bluntly in the headline “8 ASX shares with 30% to 220% upside ahead: Experts”, citing Turalco Gold’s “$1.75 target… potential capital growth of 220% over the next year” and Credit Corp’s “price target of $19.70… potential 51% upside ahead,” with named broker calls in between including Canaccord Genuity on Droneshield at $3.75, Morgan Stanley at $16 on another buy-rated name, and Citi reaffirming Seek at $24.15 rather than making a broad market call.

That is why the bullish case remains a stock-picker’s market, not a blanket endorsement of equities. The same coverage noted the “S&P/ASX 200 Index… shares rose 0.3% last week… In 2026, ASX 200 shares have managed just a 1.1% rise after the unexpected global oil shock made investors very nervous,” while another Motley Fool Australia screen stressed, “I’ve had a look through the research reports from the broking houses this week and have selected three companies tipped to deliver outsized gains over the next 12 months,” with Ord Minnett’s Acrow at 39%, Morgans’ Credit Clear at 42.9%, and Shaw and Partners’ IODM at 141.7%, underscoring how high rates, volatility, and stock-specific execution risk can still swamp optimistic models.